Mr. Keller is a highly-experienced biotech executive with special expertise in advancing the development and commercialization of antibody drugs. Prior to joining GigaGen, he served as senior director of marketing at Exelixis, a genomics-based drug discovery company, where he led the EU and U.S. commercial launch of cabozantinib into an orphan oncology indication. Preceding Exelixis, Mr. Keller held a variety of senior marketing, commercial planning and strategy roles at Achaogen, Genentech and APM/CSC Healthcare. He holds a B.S.E. in Chemical Engineering from Stanford University and an MBA from the Haas School of Business at the University of California, Berkeley.